Ireland
--:--IST
Enrolling by invitation Not applicable

Study the Mechanism and Effectiveness of Probiotics on Atopic Dermatitis

NCT07937592 · tracked via the Priya Life Science Taiwan tracker
Phase
Not applicable
Started
2026-06-30
Last updated
2026-11-16

Condition(s) studied

Atopic DermatitisEczema

Investigational drug(s) / intervention(s)

Probiotic 2 × 10^8Placebo capsuleProbiotic 2 × 10^10

Probiotic 2 × 10^8: Capsule containing 2 × 10\^8 CFU \[TBC: per gram or per capsule\] of Bifidobacterium longum and Bifidobacterium bifidum \[TBC: final strains\] isolated from breast milk and healthy infant feces. Taken orally twice daily for 12 weeks; contents may be mixed with milk or juice at no more than 40 °C.

Placebo capsule: Capsule of identical appearance containing excipient only, without probiotic bacteria. Taken orally twice daily for 12 weeks.

Probiotic 2 × 10^10: Capsule containing 2 × 10\^10 CFU \[TBC: per gram or per capsule\] of Bifidobacterium longum and Bifidobacterium bifidum \[TBC: final strains\] isolated from breast milk and healthy infant feces. Taken orally twice daily for 12 weeks; contents may be mixed with milk or juice at no more than 40 °C.

Study summary

The goal of this clinical trial is to learn whether probiotics isolated from breast milk and healthy infant feces can reduce the severity of atopic dermatitis (eczema) in children aged 3 to 18 years with moderate-to-severe disease. The main questions it aims to answer are:

* Does taking the probiotic capsule twice daily for 12 weeks reduce eczema severity, measured by the EASI SCORAD?
* Does the probiotic improve quality of life, blood markers of allergic inflammation (IgE, histamine, IL-31, T-cell subsets), and gut microbiota composition? Researchers will compare the probiotic to a placebo capsule that looks the same but contains no probiotic bacteria.

Participants will:

* Take one capsule twice daily for 12 weeks, in addition to their usual atopic dermatitis treatment
* Complete the PO-SCORAD and a quality-of-life questionnaire at baseline and weeks 2, 4, 8 and 12
* Provide stool samples at baseline and weeks 4 and 12, and a 10 mL blood sample at baseline and week 12.

Eligibility

Sex
ALL
Min age
3 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * Aged 3 to 18 years * Diagnosis of atopic dermatitis with moderate-to-severe disease, defined as an Eczema Area and Severity Index (EASI) score \> 7 at screening * Receiving regular atopic dermatitis treatment at National Cheng Kung University Hospital * Written informed consent from the participant's legal representative, with assent from participants aged 7 years and older Exclusion Criteria: * Skin disease other than atopic dermatitis * Current or planned treatment with a biologic agent (e.g., dupilumab, an anti-IL-4Rα antibody) * Current or planned treatment with an oral small-molecule immunosuppressant (e.g., upadacitinib)

Primary outcome measure(s)

  • Change in Eczema Area and Severity Index (EASI) score from baseline to week 12 — Baseline, week4, week8, week 12
    Clinician-assessed EASI. Score range 0-72; higher scores indicate more severe disease.
  • Change in gut microbial — Baseline, weeks 4 and 12
    Relative abundance (%) of the gut microbial from 16S rRNA gene (V1-V9) sequencing of stool.
  • Change in PO-SCORAD — Baseline, week4, week8, week 12
    Patient-Oriented SCORAD completed by the participant or primary caregiver (range 0-103; higher = worse).
  • Change in quality of life — Baseline, week4, week8, week 12
    For different ages, IDQOL, CDLQI, or DLQI, completed by the participant or primary caregiver.(range:0-30)
  • Change in serum total IgE — Baseline and week 12
    Serum total IgE concentration (IU/mL).
  • Change in serum histamine — Baseline and week 12
    Serum histamine concentration measured by ELISA (ng/mL).
  • Change in serum IL-4 — Baseline and week 12
    Serum interleukin-4 concentration measured by ELISA (pg/mL).
  • Change in serum IL-13 — Baseline and week 12
    Serum interleukin-13 concentration measured by ELISA (pg/mL).
  • Change in serum IL-31 — Baseline and week 12
    Serum interleukin-31 concentration measured by ELISA (pg/mL).
  • Change in white blood cell count — Baseline and week 12
    Total white blood cell count from complete blood count (cells/μL).
  • Change in absolute lymphocyte count — Baseline and week 12
    Absolute lymphocyte count (cells/μL).
  • Change in absolute CD3+ T-cell count — Baseline and week 12
    Absolute CD3+ T-cell count measured by flow cytometry (cells/μL).
  • Change in absolute CD4+ helper T-cell count — Baseline and week 12
    Absolute CD4+ T-cell count measured by flow cytometry (cells/μL).
  • Change in absolute CD8+ suppressor/cytotoxic T-cell count — Baseline and week 12
    Absolute CD8+ T-cell count measured by flow cytometry (cells/μL).
  • Change in CD4+/CD8+ T-cell ratio — Baseline and week 12
    Ratio of CD4+ to CD8+ T cells measured by flow cytometry (ratio, unitless).

Trial sites (1)

FacilityCityRegionStatus
National Cheng Kung University Hospital Tainan Taiwan
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07937592 on ClinicalTrials.gov ↗ ← All trials in Taiwan